Suzhou Huiliao Biopharmaceutical Technology Co., Ltd. specializes in the development and production of mRNA-based therapeutics, including vaccines for infectious diseases and tumor treatments. The company addresses the need for effective and scalable mRNA drug solutions by providing comprehensive clinical trial design and data analysis services.
Funding
Funding not disclosed
Founders
Product
Problem
The development and production of mRNA-based therapeutics, such as vaccines and tumor treatments, require specialized expertise and infrastructure. Traditional methods may lack the scalability and efficiency needed to meet the growing demand for these advanced therapies.
Solution
Suzhou Huiliao Biopharmaceutical Technology Co., Ltd. focuses on providing comprehensive solutions for the industrialization of nucleic acid drugs, including mRNA therapeutics and vaccines. The company offers end-to-end services encompassing mRNA drug research and development, clinical trial design, and data analysis. Huiliao Bio is dedicated to advancing mRNA technology for infectious disease vaccines, tumor vaccines, cell therapies, and protein replacement therapies.
Target Audience
The primary customers are pharmaceutical companies, research institutions, and healthcare providers seeking mRNA-based therapeutics and vaccine development solutions.
Features
- Development of mRNA drugs for infectious disease vaccines and tumor treatments
- Comprehensive clinical trial design services
- Data analysis services for clinical trials
- GMP-compliant pilot production
- Focus on mRNA technology for cell therapies and protein replacement
- R&D in veterinary mRNA vaccines